Local advantage

Theravance Biopharma Inc. is reaching a key inflection point for the first candidate to emerge from its program to develop me-better immunology therapies that act locally and avoid systemic side effects.

The company will report new data by mid-year on TD-1473, an oral pan-Janus kinase (JAK) inhibitor for ulcerative colitis (UC) that is designed to restrict its activity to the small and large intestines and metabolize quickly in the blood stream to avoid systemic circulation. ...